MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To guage various intravenous doses of sifalimumab, in Grownup people with dermatomyositis or polymyositis (NCT00533091). Main trial targets were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, while one of several exploratory ... https://ezetimibe36780.total-blog.com/not-known-facts-about-yx-2-107-56215639